SCHEMBL2090898

SCHEMBL2090898

[CH2]c1ccccc1-c1ccc(OC)c(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
ALDH1A1 P00352 6/20 0.48
KDM4E B2RXH2 5/20 0.48
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
HSD17B10 Q99714 3/20 0.48
TSHR P16473 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
HPGD P15428 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
PDE4A P27815 1/20 0.47
TP53 P04637 1/20 0.46
ADORA1 P30542 1/20 0.46
HPGDS O60760 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
ACACA Q13085 1/20 0.45
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30452106 0.86 KDM4E (0.57) MEN1KMT2AL3MBTL1ALDH1A1KDM4E
SCHEMBL5478760 0.82 PTPRC (0.61) MEN1KMT2AL3MBTL1ALDH1A1KDM4E
SCHEMBL3230744 0.82 ABL1 (0.51) ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL5465021 0.79 KIT (0.60) MEN1KMT2AL3MBTL1ALDH1A1KDM4E
SCHEMBL28193876 0.79 CA1 (0.57) MEN1KMT2AALDH1A1KDM4ENPC1
SCHEMBL29788143 0.78 ERN1 (0.54) MEN1KMT2AL3MBTL1ALDH1A1KDM4E
SCHEMBL395115 0.78 KIT (0.61) MEN1KMT2AL3MBTL1ALDH1A1KDM4E
SCHEMBL21345520 0.78 KIT (0.49) MEN1KMT2AL3MBTL1ALDH1A1KDM4E
SCHEMBL30610422 0.78 KIT (0.61) MEN1KMT2AL3MBTL1ALDH1A1KDM4E
SCHEMBL28212779 0.78 MEN1 (0.64) MEN1KMT2AL3MBTL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 MEN1 4525/4885KMT2A 3324/4885L3MBTL1 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.